Ashvattha Therapeutics has recently announced several key developments in its medical research and clinical trials. The company enrolled the first patient in a two-stage Phase 2 study of D-4517.2, a subcutaneous anti-VEGF candidate for treating Wet AMD and DME. This marks a significant step forward in the development of treatments for these conditions.
At the 2022 Alzheimer’s Association International Conference (AAIC), Ashvattha presented preclinical data demonstrating that its hydroxyl dendrimer-based imaging agent, [18F]OP-801, can detect early-stage neuroinflammation with higher sensitivity than TSPO-PET. This highlights the potential of [18F]OP-801 as a promising tracer for visualizing neuroinflammation progression.
Additionally, Ashvattha announced the publication of data from a Phase 2a clinical trial for OP-101 in severe COVID-19 patients. The data showed that OP-101, delivered intravenously, significantly reduced inflammatory and neuroinflammatory markers and improved clinical outcomes, suggesting its potential to treat systemic inflammation and neuronal injury.
The company also shared preclinical data at the 2022 Neurofibromatosis (NF) Conference, demonstrating the potential of hydroxyl dendrimer therapeutics to reduce toxicity in the targeted treatment of plexiform neurofibroma. This research indicates a promising direction for reducing side effects in cancer treatment.
In a significant financial development, Ashvattha Therapeutics secured $69 million in Series B financing and entered an exclusive licensing agreement with Huadong Medicine, advancing the development of hydroxyl dendrimer-based precision medicines. This funding and partnership are expected to accelerate the company's research and development efforts in creating novel therapeutics.
